Posts

Posted on

Triterras Hires Perry Mangers as Vice President of Financial Reporting

Newly created role reaffirms company’s commitment to global financial transparency

SINGAPORE, Sept. 15, 2021 (GLOBE NEWSWIRE) — Triterras Inc. (Nasdaq: TRIT, TRITW) (“Triterras” or the “Company”), a leading fintech company focused on trade and trade finance, today announced the appointment of Perry Mangers, CPA, to the newly created role of Vice President of Financial Reporting. He will report to Chief Financial Officer Alvin Tan.

Mangers is a finance professional with more than 20 years of wide-ranging corporate and board-level experience. His areas of specialty have included initial public offerings, global reporting, financial controls, SOX compliance, financial systems implementations, technical accounting and M&A advisory functions. He will be responsible for financial reporting in compliance with the requirements of the U.S. Securities and Exchange Commission and International Financial Reporting Standards.

Most recently, Mangers was Director of Financial Reporting for Parsons (NYSE: PSN), a technology-focused defense, intelligence, security, and infrastructure engineering firm. Prior to Parsons, Mangers held the role of Vice President, Corporate Accounting, at Jacobs Engineering Group (NYSE: J), a $13 billion technical professional services firm, where he led the company’s financial reporting, general accounting, and FP&A teams.

“Perry is an experienced decision maker with outstanding analytical skills that will greatly benefit Triterras as we address our regulatory obligations. I’m confident he can adeptly fulfill the demands of the role so that we can deliver timely financial information to investors and the marketplace,” said Alvin Tan, Chief Financial Officer, Triterras.

Mangers brings a wealth of international finance experience to strengthen Triterras’ global reporting practice. During his time at Jacobs, Mangers relocated to Sydney for two years to assist with the integration of the $1.2 billion acquisition of Sinclair Knight Merz. He also led Oracle financial system implementations in Canada, England and Ireland. He was Finance Director for Jacobs’ Irish operations during a period of unprecedented growth.

“I’m excited to join a fast-paced, sophisticated company at a pivotal moment in its growth story. I look forward to working collaboratively with the finance team and utilizing my deep financial background to create value for the business around the world,” said Mangers.

Mangers holds a Bachelor of Business Administration in Finance from the University of Texas at Arlington and was licensed as a Certified Public Accountant in California.

About Triterras

Triterras is a leading fintech company focused on trade and trade finance. It launched and operates Kratos™—one of the world’s largest trading and trade finance platforms that connects and enables commodity traders to trade and source capital from lenders directly online. For more information, please visit triterras.com or email us at [email protected].

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Triterras’ actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include Triterras’ expectations with respect to future performance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Triterras’ control and are difficult to predict. Factors that may cause such differences include but are not limited to risks and uncertainties incorporated by reference under “Risk Factors” in Triterras’ Form 20-F (001-39693) filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2020 (the “Form 20-F”) and in Triterras’ other filings with the SEC. Triterras cautions that the foregoing list of factors is not exclusive. Triterras cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Triterras does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Investor Relations Contacts:

Jim Groh, Triterras Inc.
Mobile: +1 (678) 237-7101
Email: [email protected]

Gateway Investor Relations

Cody Slach and Matt Glover
Office: +1 (949) 574-3860
Email: [email protected]

Media Contacts:

Gregory Papajohn, Office of Corporate Communications, Triterras, Inc.
Mobile: +1 (917) 287-3626
Email: [email protected]



Posted on

Home BancShares, Inc. Announces Triple Accretive Acquisition and Entry to Texas Through a Combination with Happy Bancshares, Inc., Creating an Expansive Southern Banking Institution Stretching from Panhandle to Panhandle

CONWAY, Ark. and AMARILLO, Texas, Sept. 15, 2021 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NASDAQ: HOMB) (“Home BancShares” or “HOMB”), the parent company of Centennial Bank, and Happy Bancshares, Inc. (“Happy Bancshares”), the parent company of Happy State Bank, jointly announced today that they have entered into a definitive merger agreement pursuant to which Home BancShares will acquire Happy Bancshares in an all-stock merger, with Home BancShares as the surviving entity.

The combination grants Home BancShares access to the high growth Texas market and establishes the combined entity as a dominant Southern institution with the opportunity to leverage each company’s track record of performance, integration and leadership. The combination positions Home BancShares to expand further into Texas and potentially acquire additional institutions over time.

Under the terms of the definitive merger agreement, which was unanimously approved by the Boards of directors of both companies, Happy Bancshares shareholders upon closing of the merger will receive 2.17 shares of Home BancShares stock for each share of Happy Bancshares they own and will begin receiving quarterly dividends declared by Home BancShares. Based on a volume-weighted average closing price per share of Home BancShares stock of $21.77 during the 20-trading-day period ending on September 13, 2021, the per share consideration value is $47.24 and the aggregate transaction value is approximately $919 million.

The transaction is consistent with Home BancShares’ M&A track record and is expected to be immediately triple accretive: resulting in increases to earnings per share of 5.5%1 and 9.2%1 for 2022 and 2023, respectively; book value per share of 5.1%2 and tangible book value per share of 1.5%2. Following the completion of this transaction, Home BancShares will continue to have a robust capital position along with an improved operating profile. The pro forma bank will be approximately $23.3 billion2 in assets, $13.4 billion2 in loans and $18.7 billion2 in deposits and will be one of the 75 largest banks headquartered in the United States3.

Home BancShares will continue to be headquartered in Conway, Arkansas and operate as Centennial Bank in its current markets. As part of the transaction, Home BancShares will add J. Pat Hickman, current Happy Bancshares Chairman, to its Board of Directors. Happy Bancshares CEO, Mikel Williamson will join the Centennial Bank executive team while additional Happy State Bank executives are to maintain leadership roles in Texas markets. Following completion of the merger, branches located in Texas will be branded Happy State Bank, a Division of Centennial Bank.

“Happy State Bank is excited to join forces with one of the top-performing banks in the country,” said J. Pat Hickman, Chairman of Happy Bancshares. “Centennial Bank is one of the few banks that has grown even faster and stronger than Happy, and with a similar mix of serving both small towns and metropolitan areas, they check every box when it comes to taking care of customers, stockholders and employees. It’s just a great match. I have to say it…we’re happy to be joining the HOMB team.”

John Allison, Co-Founder, Chairman, President and CEO of Home BancShares, stated, “We have expressed our desire to return to Texas for several years. We are thrilled to have found such a quality bank to partner with to make this expansion a reality. As strong as HOMB’s loan yield is, Happy’s is even stronger. Combine that with joining forces with their founder, J. Pat Hickman, quality employees and 1,300 loyal individual shareholders, makes this a very attractive combination. Making a ‘triple accretive’ transaction, with no earn-back period (which includes $55 million in deal costs plus $28 million to be taken immediately after close reflective of the CECL “double count”) and now being in two of the best growth markets in the U.S. (Texas and Florida) should reap strong returns for our shareholders.”

“Centennial is one of the best banks in the country and Happy is one of the best banks in Texas when it comes to taking care of their stockholders, customers, employees and communities. It’s exciting to see two great community banks with great cultures join forces,” added Mikel Williamson, President and CEO of Happy State Bank.

The merger is expected to close early in the first quarter of 2022, subject to satisfaction of customary closing conditions, including customary regulatory approvals and approval by the shareholders of each company.

Piper Sandler served as the financial advisor to Home BancShares and provided a fairness opinion, with Mitchell, Williams, Selig, Gates & Woodyard serving as legal advisor. Stephens Inc. served as financial advisor to Happy Bancshares and provided a fairness opinion, with Alston & Bird serving as legal advisor.

                

1 Assumes 75% realization of cost savings in 2022 and full realization of cost savings in 2023
2 Estimates are based on 12/31/21 projections
3 By deposit market share. Source S&P Global Market Intelligence

Conference Call & Presentation

Management will conduct a conference call to review this information at 1:00 p.m. CT (2:00 ET) on Wednesday, September 15, 2021. We encourage all participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10160040/ed0711ac98. Callers who pre-register will be given dial-in instructions and a unique PIN to gain immediate access to the live call. Participants may pre-register now, or at any time prior to the call, and will immediately receive simple instructions via email. The Home BancShares conference call will also be automatically scheduled as an event in your Outlook calendar.

Those without internet access or unable to pre-register may dial in and listen to the live call by calling 1-877-508-9586 and asking for the Home BancShares conference call. A replay of the call will be available by calling 1-877-344-7529, Passcode: 10160040, which will be available until September 22, 2021 at 10:59 p.m. CT (11:59 ET). Internet access to the call will be available live or in recorded version on the Company’s website at www.homebancshares.com under “Investor Relations” for 12 months.

Additional information regarding the acquisition is provided in a supplemental presentation available on the Company’s website at www.homebancshares.com, under the “Investor Relations” section.

About Home BancShares

Home BancShares operates as the bank holding company for Centennial Bank that provides commercial and retail banking, and related financial services to businesses, real estate developers and investors, individuals, and municipalities. Centennial Bank has branch locations in Arkansas, Florida, South Alabama and New York City. The Company’s common stock is traded through the NASDAQ Global Select Market under the symbol “HOMB.” The company was founded in 1998 and is headquartered in Conway, Arkansas. Visit www.homebancshares.com or www.my100bank.com for more information.

About Happy Bancshares

Happy Bancshares operates as the bank holding company for Happy State Bank that offers a broad range of financial services and products through its current network of bank branches in communities across the Texas Panhandle, South Plains, Austin, Central Texas and the Dallas/Fort Worth Metroplex. Happy State Bank was founded in 1908 in Happy, Texas and today is headquartered in Amarillo, Texas. Visit www.HappyBank.com for more information.

Forward-Looking Statements

This release contains forward-looking statements which include, but are not limited to, statements about the benefits of the business combination transaction involving Home BancShares, Inc. (“Home”) and Happy Bancshares, Inc. (“Happy”), including the combined company’s future financial and operating results, plans, expectations, goals and outlook for the future. Statements in this press release that are not historical facts should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements of this type speak only as of the date of this press release. By nature, forward-looking statements involve inherent risk and uncertainties. Various factors could cause actual results to differ materially from those contemplated by the forward-looking statements, including, but not limited to, (i) the possibility that the acquisition does not close when expected or at all because required regulatory, shareholder or other approvals and other conditions to closing are not received or satisfied on a timely basis or at all; (ii) the possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (iii) the risk that the benefits from the transaction may not be fully realized or may take longer to realize than expected, including as a result of changes in general economic and market conditions, ongoing or future effects of the COVID-19 pandemic, interest and exchange rates, monetary policy, laws and regulations and their enforcement, and the degree of competition in the geographic and business areas in which Home and Happy operate; (iv) the ability to promptly and effectively integrate the businesses of Home and Happy; (v) the reaction to the transaction of the companies’ customers, employees and counterparties; and (vi) diversion of management time on acquisition-related issues. Additional information on factors that might affect Home’s financial results is included in its Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 26, 2021. Home assumes no obligation to update the information in this press release, except as otherwise required by law.

Additional Important Information and Where to Find It

This press release may be deemed to be solicitation material in respect of the proposed transaction by Home and Happy. In connection with the proposed acquisition, Home intends to file with the Securities and Exchange Commission (the “SEC”) a Registration Statement on Form S-4 (the “Registration Statement”) to register the shares of Home common stock to be issued to shareholders of Happy in connection with the transaction. The Registration Statement will include a Joint Proxy Statement of Home and Happy and a Prospectus of Home, as well as other relevant materials regarding the proposed merger transaction involving Home and Happy. INVESTORS AND SECURITY HOLDERS OF HOME AND HAPPY ARE ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED WITH THE SEC IN CONNECTION WITH THE MERGER OR INCORPORATED BY REFERENCE IN THE JOINT PROXY STATEMENT/PROSPECTUS BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION REGARDING THE PROPOSED MERGER TRANSACTION. Investors and security holders may obtain free copies of these documents, once they are filed, and other documents filed with the SEC on the SEC’s website at http://www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by Home at Home’s website at http://www.homebancshares.com, Investor Relations, or by contacting Donna Townsell, by telephone at (501) 328-4625.

Participants in Solicitation

Home and Happy and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Home and Happy in connection with the merger transaction. Information about the directors and executive officers of Home and their ownership of Home common stock is set forth in the proxy statement for Home’s 2021 Annual Meeting of Shareholders, as filed with the SEC on Schedule 14A on March 2, 2021. Information about the directors and executive officers of Happy and their ownership of Happy common stock will be set forth in the Joint Proxy Statement/Prospectus to be included in the Registration Statement. Additional information regarding the interests of those participants and other persons who may be deemed participants in the transaction may be obtained by reading the Joint Proxy Statement/Prospectus regarding the merger transaction. Free copies of this document may be obtained as described in the preceding paragraph when it becomes available.

Investor Contact

Donna Townsell
Director of Investor Relations
Home BancShares, Inc.
(501) 328-4625



Posted on

Smart Sewer Technology Satisfies EPA Consent Decree, Saves City $400 Million

Smart Sewer Technology Satisfies EPA Consent Decree, Saves City $400 Million

DoJ, EPA Have Endorsed South Bend’s Updated Long Term Plan Requiring 60% Less Infrastructure Investment

Delivers Better Environmental Outcomes, Exceeding Original Overflow And Pollution Control Requirements

RYE BROOK, N.Y.–(BUSINESS WIRE)–
Global water technology company, Xylem (NYSE:XYL), is delivering the advanced “smart sewer” system enabling the City of South Bend, Indiana, to exceed the requirements of a wastewater consent decree for 60% less capital investment (CapEx) than originally planned.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005648/en/

Smart Sewer Technology Satisfies EPA Consent Decree, Saves City $400 Million (Photo: Business Wire)

Smart Sewer Technology Satisfies EPA Consent Decree, Saves City $400 Million (Photo: Business Wire)

The US Environmental Protection Authority (EPA) and the US Department of Justice (DoJ) have now formally endorsed the City’s long-term sewer plan, based on the advanced technology. The EPA, the DoJ and the City of South Bend originally entered into a consent decree in 2012 in response to the City’s aging sewer infrastructure that frequently overflowed, discharging millions of gallons of sewage and stormwater into the landmark St. Joseph River each year. The plan to address the problem was set to cost South Bend ratepayers $713 million in capital improvements. But the parties have now announced they are amending the original agreement with a revised plan based on “smart sewer” technology. The City’s new approach, using Xylem’s wastewater network optimization solution, provides “better protection at lower cost,” according to the EPA.

“We are so pleased to be partnering with the visionary team at the City of South Bend, providing the digital innovation and insights to make this transformation possible,” said Patrick Decker, Xylem’s CEO. “Their hard work has now resulted in a ground-breaking outcome which will save every family in the city thousands of dollars while enabling them to enjoy a more beautiful St. Joseph River, and have access to cleaner water more affordably.”

“We will spend 400 million dollars less than originally estimated, achieving greater environmental benefit and level of service, just by optimizing the existing system in the ground,” said Eric Horvath, Director of Public Works for the City of South Bend.

“Capturing and using data from sewers used to sound strange,” Decker continued. “But our water infrastructure increasingly has to deal with sudden and extreme weather events, while meeting regulatory requirements and protecting our communities. South Bend is among a growing number of cities modernizing their water systems with advanced digital solutions to make their communities more resilient. We are proud to serve them in this journey.”

The City of South Bend’s revised plan consists of a monitoring system of more than 165 sensors and software agents located throughout the City’s urban watershed, managing 13 automated gates and valves. Real-time decision support technology enables the network to react to sudden wet weather events and avoid flooding by quickly moving flows to under-utilized parts of the network. Operators receive overflow information via control room screens, smartphones and tablets – giving them the ability to override the system at any time, if needed.

The result has been a dramatic reduction in combined sewer overflow volumes (roughly 1 billion gallons per year), and a more-than 50% drop in E. coli concentration in the St. Joseph River. In addition to the capital works savings, the City is also benefiting from $1.5 million per year in reduced operations and maintenance costs.

The City has implemented its new control plan based on the Xylem solution working alongside deployment partners American Structurepoint, LimnoTech, and Stantec.

About Xylem

Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 16,000 diverse employees delivered revenue of $4.88 billion in 2020. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.

Media

Houston Spencer

+1 (914) 240-3046

[email protected]

KEYWORDS: Indiana New York United States North America

INDUSTRY KEYWORDS: Environment Technology Other Energy Utilities Other Technology Professional Services Other Natural Resources Energy Natural Resources Other Professional Services

MEDIA:

Logo
Logo
Photo
Photo
Smart Sewer Technology Satisfies EPA Consent Decree, Saves City $400 Million (Photo: Business Wire)
Posted on

atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“Loan Agreement”) with strategic partner IntelGenx Technologies Corp. (“IntelGenx”) to support IntelGenx’s conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock Exchange (“TSX”). Completion of the uplisting and the commencement of trading of IntelGenx’s common shares, 8% convertible debentures with a maturity date of June 30, 2022, and share purchase warrants expiring on February 11, 2023 is subject to the satisfaction by IntelGenx of all of the final conditions of listing.

atai has agreed to increase the principal amount of its outstanding US$2,500,000 loan to IntelGenx by an additional US$6,000,000, with US$3,000,000 to become available to IntelGenx in each of January 2022 and January 2023, subject to customary conditions. The loan is in addition to atai’s previously announced initial equity investment of an approximately 25% interest in IntelGenx. The loan bears interest at a rate of 8% per annum, payable at maturity, and matures in January 2024. The borrower under the secured loan is IntelGenx’s wholly-owned subsidiary, IntelGenx Corp., and the loan is guaranteed by IntelGenx.

As part of the strategic partnership, IntelGenx partnered exclusively with atai to develop formulations of compounds for the prevention or treatment of mental health diseases or disorders, including compounds that have psychedelic, entactogenic and/or oneirophrenic properties (such as DMT and psilocybin, among others). atai agreed to increase the loan principal in part on the basis of early data generated from its ongoing feasibility studies conducted with IntelGenx.

“We are proud to deepen our relationship with atai, while strengthening our positions of leadership and boldly innovating novel psychedelic therapies,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “I’m excited about our companies’ mutual efforts to advance our robust pipelines, while finding synergistic ways to work together to develop better compounds and modes of delivery to benefit patients.”

“This transaction illustrates our confidence in IntelGenx’s film technology and the potential it has in the development of product candidates to treat mental health disorders,” said Florian Brand, CEO of atai. “We look forward to collaborating to transition this innovative film delivery technology into the clinic.”

About atai

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai’s mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai has offices in New York, London, and Berlin. For more information, please visit www.atai.life.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-Looking Information

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things,
the uplisting of IntelGenx to the TSX and continued strategic cooperation between atai and IntelGenx. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond our control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including without limitation: we are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future; we will require substantial additional funding to achieve our business goals, and if we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development efforts; our limited operating history may make it difficult to evaluate the success of our business and to assess our future viability; we have never generated revenue and may never be profitable; our product candidates contain controlled substances, the use of which may generate public controversy; clinical and preclinical development is uncertain, and our preclinical programs may experience delays or may never advance to clinical trials; we currently rely on qualified therapists working at third-party clinical trial sites to administer certain of our product candidates in our clinical trials and we expect this to continue upon approval, if any, of our current or future product candidates; if third-party sites fail to recruit and retain a sufficient number of therapists or effectively manage their therapists, our business, financial condition and results of operations would be materially harmed; we cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized; research and development of drugs targeting the central nervous system, or CNS, is particularly difficult, and it can be difficult to predict and understand why a drug has a positive effect on some patients but not others; we face significant competition in an environment of rapid technological and scientific change; third parties may claim that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent or delay our development and commercialization efforts; a change in our effective place of management may increase our aggregate tax burden; we identified material weaknesses in connection with our internal control over financial reporting; and a pandemic, epidemic, or outbreak of an infectious disease, such as the COVID-19 pandemic, may materially and adversely affect our business, including our preclinical studies, clinical trials, third parties on whom we rely, our supply chain, our ability to raise capital, our ability to conduct regular business and our financial results. Other risk factors include the important factors described in the section titled “Risk Factors” in our final prospectus, filed with the Securities and Exchange Commission (“SEC”) on June 21, 2021 pursuant to Rule 424(b) under the Securities Act, and in our other filings with the SEC, that may cause our actual results, performance or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements.

Any forward-looking statements made herein speak only as of the date of this press release, and you should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, performance, or achievements reflected in the forward-looking statements will be achieved or will occur. Except as required by applicable law, we undertake no obligation to update any of these forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or revised expectations.

Contact Information

For atai Life Sciences:

Investor Contact:

Greg Weaver
ATAI – Chief Financial Officer
Email: [email protected]

Media Contact:

Anne Donohoe
KCSA Strategic Communications
Phone: +1 (212) 896-1265
Email: [email protected]

For IntelGenx:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
[email protected]

Or

Andre Godin, CPA, CA
President and CFO
IntelGenx Technologies Corp.
(514) 331-7440 ext 203
[email protected]

 



Posted on

QAD Precision President Corey Rhodes to Speak at 2021 PARCEL Forum

QAD Precision President Corey Rhodes to Speak at 2021 PARCEL Forum

Global trade logistics leader to showcase the value of connecting parcel shipping with global trade in the cloud at booth 206

SANTA BARBARA, Calif.–(BUSINESS WIRE)–QAD Precision, an industry-leading provider of global trade and transportation execution solutions, will exhibit at the 2021 PARCEL Forum, September 14-16, in Washington, D.C. QAD Precision President Corey Rhodes is a featured speaker at the event, presenting on the benefits of moving parcel shipping to the cloud. QAD Precision is a division of QAD Inc. (NASDAQ: QADA) (NASDAQ:QADB).

QAD Precision offers a global, multilingual, multi-carrier parcel shipping solution along with a comprehensive carrier network that services every region of the world, along with a centralized portal for 360-degree visibility and exception alerts as parcels move through the carrier network.

“Parcel shipping is in our DNA. As we have seen in the last eighteen months of skyrocketing shipping volumes, moving parcel shipments efficiently and cost effectively has been a growing challenge for many companies,” said Rhodes. “At the same time, cross-border shipments are increasing, and companies need to be able to meet global trade regulations as well as provide excellent service to customers, no matter where they are. With our comprehensive global parcel carrier network and global trade solutions, we can help companies optimize their parcel shipping, no matter where they ship from or ship to.”

Rhodes will speak at the event Wednesday, September 15, at 12:20 to 1:00pm EDT. In his session, “Why Cloud, Why Now,” Rhodes will share:

  • The benefits of moving to the cloud
  • Why parcel shipping should be an integral part of a successful supply chain strategy
  • How to leverage the cloud’s flexibility, scalability and connectivity.

QAD Precision’s Chris Shea and Jeff Flanagan will be on hand to answer questions in booth 206. Attendees are invited to drop by to learn more about how QAD Precision helps enterprises to simplify global parcel shipping, mitigate compliance risk, and optimize global trade and transportation processes to increase logistics ROI.

About QAD Precision – Trusted Global Trade and Transportation Execution

QAD Precision, a division of QAD Inc., provides industry-leading global trade compliance, and multi carrier transportation execution solutions from a single, integrated platform. An ISO-certified company, QAD Precision’s scalable and extensible solution easily integrates with existing ERP and WMS solutions. Industry leaders in every region of the world rely on QAD Precision’s global support centers to leverage thousands of carrier services and manage millions of global trade and shipping transactions every day. For more information about QAD Precision, visit www.qadprecision.com.

Note to Investors: This press release contains certain forward-looking statements made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding projections of revenue, income and loss, capital expenditures, plans and objectives of management regarding the company’s business, future economic performance or any of the assumptions underlying or relating to any of the foregoing. Forward-looking statements are based on the company’s current expectations. Words such as “expects,” “believes,” “anticipates,” “could,” “will likely result,” “estimates,” “intends,” “may,” “projects,” “should,” “would,” “might,” “plan” and variations of these words and similar expressions are intended to identify these forward-looking statements. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to: risks associated with our cloud service offerings, such as defects and disruptions in our services, our ability to properly manage our cloud service offerings, our reliance on third-party hosting and other service providers, and our exposure to liability and loss from security breaches; demand for the company’s products, including cloud service, licenses, services and maintenance; pressure to make concessions on our pricing and changes in our pricing models; protection of our intellectual property; dependence on third-party suppliers and other third-party relationships, such as sales, services and marketing channels; changes in our revenue, earnings, operating expenses and margins; the reliability of our financial forecasts and estimates of the costs and benefits of transactions; the ability to leverage changes in technology; defects in our software products and services; third-party opinions about the company; competition in our industry; the ability to recruit and retain key personnel; delays in sales; timely and effective integration of newly acquired businesses; economic conditions in our vertical markets and worldwide; exchange rate fluctuations; and the global political environment. For a more detailed description of the risk factors associated with the company and factors that may affect our forward-looking statements, please refer to the company’s latest Annual Report on Form 10-K and, in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter. Management does not undertake to update these forward-looking statements except as required by law.

QAD Precision

Anne Sexton

[email protected]

+353 1 406 0780

QAD Inc.

Scott Matulis

Public Relations

818-451-8918

[email protected]

or

Evan Quinn

Analyst Relations

617-869-7335

[email protected]

KEYWORDS: California District of Columbia United States North America

INDUSTRY KEYWORDS: Data Management Communications Technology Logistics/Supply Chain Management Transport Software Public Relations/Investor Relations

MEDIA:

Logo
Logo
Posted on

Alpine Immune Sciences Announces $91 Million Private Placement

Alpine Immune Sciences Announces $91 Million Private Placement

SEATTLE–(BUSINESS WIRE)–
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, as described below, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately $91 million, before deducting offering expenses. The private placement is being led by Frazier Life Sciences Public Fund with participation from Decheng Capital, BVF Partners, TCG X, Avidity Partners, OrbiMed, Omega Fund, and Logos Capital, among others.

“As a long-term backer of Alpine, we are impressed by the company’s progress and their emergence as a leader in both immunology and immuno-oncology,” said James Topper, M.D., Ph.D, Managing General Partner of Frazier’s Life Sciences team. “This financing will help the company to pursue a focused and rapid development plan for ALPN-303, a potentially best-in-class inhibitor of the BAFF and APRIL pathways, and will also support the ongoing development of ALPN-202 as it enters monotherapy expansion cohorts next year and expands its development efforts in combination with Keytruda. We are pleased to lead this syndicate of strong investors and look forward to supporting the company in this next phase of growth.”

Pursuant to the terms of the securities purchase agreement, at the closing of the private placement, Alpine will issue approximately 6.5 million shares of common stock and approximately 3.2 million prefunded warrants to purchase the same number of shares of common stock. Both the common stock and prefunded warrants will be sold at a price of $9.40 per share or prefunded warrant, respectively. The prefunded warrants will have a per share exercise price of $0.001 and will be exercisable at any time on or after the closing date. The price of the common stock and prefunded warrants is at a 4.4% premium to the closing price of $9.00 per share of Alpine’s common stock on the Nasdaq Global Market on September 14, 2021.

The private placement is expected to close on or about September 17, 2021, subject to the satisfaction of customary closing conditions. Additional details regarding the private placement will be included in a Form 8-K to be filed by Alpine with the Securities and Exchange Commission (“SEC”).

Alpine intends to use the net proceeds to support the expansion of its pipeline, including the development of ALPN-303 in lupus and other B cell-mediated inflammatory diseases. In addition, net proceeds will be used to support the further clinical development of ALPN-202 as well as Alpine’s discovery programs and general corporate purposes.

In connection with the entry into the securities purchase agreement, an affiliate of Frazier Life Sciences Public Fund entered into an exchange agreement with Alpine, pursuant to which Alpine will exchange an aggregate of 1.2 million shares of common stock currently held by the affiliate of Frazier Life Sciences Public Fund for prefunded warrants to purchase an aggregate of 1.2 million shares of common stock, which prefunded warrants have identical terms to the prefunded warrants sold pursuant to the securities purchase agreement. After giving effect to the exchange of 1.2 million shares of common stock and the issuance of the approximately 6.5 million shares pursuant to the securities purchase agreement, the number of shares of Alpine’s outstanding common stock immediately after this offering would be approximately 29.2 million as of July 30, 2021. The closing of the exchange is subject to customary closing conditions and is contingent upon and will occur immediately following the closing of the private placement.

The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Alpine has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable in connection with the private placement and upon exercise of the prefunded warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of private equity capital to healthcare companies. With more than $6.2 billion total capital raised, Frazier has invested in more than 200 companies with transaction types ranging from buyouts of profitable healthcare companies to venture capital and company creation. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier has offices in Seattle, Wash., and Menlo Park, Calif., and invests broadly across the U.S., Canada and Europe. For more information about Frazier Healthcare Partners, please visit www.frazierhealthcare.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact, and include statements regarding Alpine’s platform technology, potential therapies, clinical development plans and the timing thereof, the receipt of potential milestones under Alpine’s collaborations, the anticipated closing of the private placement and the exchange and the timing thereof, and the expected receipt and use of proceeds from the private placement. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: Alpine’s development programs may not advance into the clinic, succeed in the clinic or result in approved products on a timely or cost-effective basis or at all; Alpine’s assumptions regarding its planned expenditures and sufficiency of its cash to fund operations may be incorrect; Alpine may not achieve additional milestone payments pursuant to its collaborations; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in Alpine’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Alpine undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

The Alpine logo is a registered trademark or trademark of Alpine Immune Sciences, Inc. in various jurisdictions.

Investor Relations

Alex Sharif

Director, Investor Relations and Corporate Development

Alpine Immune Sciences, Inc

206-788-4545

[email protected]

Media Relations

Michael Beyer

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Posted on

Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Cyclo Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

– Live webcast presentation on Wednesday, September 22nd at 10:45 AM ET

GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Sharon Hrynkow, PhD, Chief Scientific Officer and Senior Vice President for Medical Affairs of Cyclo Therapeutics, will present at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on September 22, 2021 at 10:45 AM ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

The live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website (www.cyclotherapeutics.com). The webcast replay will be archived for 90 days following the live presentation.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (www.ClinicalTrials.govNCT02939547, NCT02912793, NCT03893071 and NCT04860960). The Company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.

Investor Contact:

JTC Team, LLC

Jenene Thomas

(833) 475-8247

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Health Genetics Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Posted on

Duke Energy announces notice of redemption of all Junior Subordinated Debentures due Jan. 15, 2073

PR Newswire

CHARLOTTE, N.C., Sept. 15, 2021 /PRNewswire/ — Duke Energy Corporation today announced that it has issued a notice of redemption for all of its outstanding 5.125% Junior Subordinated Debentures due Jan. 15, 2073 (NYSE: DUKH) (CUSIP: 26441C303) (“the debentures”) at a redemption price (“redemption price”) of 100% of the principal amount thereof plus accrued and unpaid interest to but excluding October 7, 2021, the redemption date.

The redemption price for the debentures will be equal to $25 (the principal amount of each debenture) plus accrued and unpaid interest from July 15, 2021, to but excluding Oct. 7, 2021, in the amount per debenture of $0.2918402778. The total principal amount of the debentures is $500 million.

On the redemption date, provided that the trustee has received sufficient funds to complete the redemption, the debentures will become due and payable and interest will cease to accrue. The paying agent for the debentures is The Bank of New York Mellon, Attn: Corporate Trust Window, 111 Sanders Creek Parkway, East Syracuse, N.Y. 13057.

Duke Energy

Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America’s largest energy holding companies. Its electric utilities serve 7.9 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 51,000 megawatts of energy capacity. Its natural gas unit serves 1.6 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The company employs 27,500 people. 

Duke Energy is executing an aggressive clean energy strategy to create a smarter energy future for its customers and communities – with goals of at least a 50 percent carbon reduction by 2030 and net-zero carbon emissions by 2050. The company is a top U.S. renewable energy provider, on track to own or purchase 16,000 megawatts of renewable energy capacity by 2025. The company also is investing in major electric grid upgrades and expanded battery storage, and exploring zero-emitting power generation technologies such as hydrogen and advanced nuclear. 

Duke Energy was named to Fortune’s 2021 “World’s Most Admired Companies” list and Forbes’ “America’s Best Employers” list. More information is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos and videos. Duke Energy’s illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook. 

Forward-looking information

This document includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based on management’s beliefs and assumptions and can often be identified by terms and phrases that include “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will,” “potential,” “forecast,” “target,” “guidance,” “outlook” or other similar terminology. Various factors may cause actual results to be materially different than the suggested outcomes within forward-looking statements; accordingly, there is no assurance that such results will be realized. For details on the uncertainties that may cause our actual future results to be materially different than those expressed in our forward-looking statements, see our 2019 Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC and available at the SEC’s website at sec.gov. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than described. Forward-looking statements speak only as of the date they are made. Duke Energy expressly disclaims an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media contact: Meredith Archie
800.559.3853

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/duke-energy-announces-notice-of-redemption-of-all-junior-subordinated-debentures-due-jan-15-2073-301377580.html

SOURCE Duke Energy

Posted on

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

HOUSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer, will present at the Life Science Investor Forum taking place September 16, 2021. The live, virtual presentation can be accessed via the conference’s virtual platform by registered conference attendees.

Mr. Arthur will provide an overview of Salarius’ business and highlight recent corporate and clinical achievements, as well as anticipated milestones in the clinical programs for seclidemstat, an oral, reversible LSD1 inhibitor. Salarius is currently advancing a Phase 1/2 dose-expansion clinical trial evaluating seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide (TC) as a potential second- and third-line therapy for Ewing sarcoma, and as a single-agent treatment for other FET-rearranged sarcomas. In addition, Mr. Arthur will also discuss the Phase 1/2 clinical trial recently initiated by MD Anderson Cancer Center to study seclidemstat in combination with azacytidine as a potential treatment for hematologic cancers.

Details of the presentation are as follows: 

Event: Life Science Investor Forum
Date: September 16, 2021
Time: 12:30-1:00 p.m. ET
Registration: https://bit.ly/3mKt7tj

The Life Science Investor Forum is a live, interactive, online event where investors are invited to ask the company questions in real-time. It is recommended that investors pre-register for the forum and run the online system check to expedite participation and receive event updates.

Following the conclusion of the event, a recording of Mr. Arthur’s presentation will be available under “Events & Presentations” in the Investors section of the Company’s website at http://www.salariuspharma.com.

More information about the Life Science Investor Forum is available at www.lifesciencesinvestorforum.com.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.

Contact

Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA (Investors)
(212) 375-2664
[email protected]

Johanna Bennett (Media)
(212) 375-2686 
[email protected]



Posted on

Sasol, Haldor Topsøe expand G2LTM licensing collaboration to grow sustainable synthetic fuels and chemicals globally

PR Newswire

JOHANNESBURG, Sept. 15, 2021 /PRNewswire/ — Haldor Topsøe and Sasol have expanded collaboration to jointly license and develop their technologies for sustainable liquid fuels and chemicals production through Fischer-Tropsch (FT) technology.

Sasol and Topsøe currently offer integrated end-to-end solutions to produce synthetic fuels and chemicals. Topsøe’s SynCOR™ and Sasol’s Low Temperature Fischer-TropschTM technologies have been licensed into Gas-to-Liquid (GTL) ventures, most recently Uzbekistan GTL, which is in the final stages of construction.

Building on this solid technology and operational foundation, Sasol and Topsøe now offer integrated end-to-end solutions to produce sustainable fuels and chemicals, specifically Power-to-Fuels or e-Fuels, utilising sustainable carbon sources or CO2, green hydrogen and renewable energy.

“We need to make cleaner alternatives for the future transportation fuels. This new initiative builds on an already successful partnership with Sasol, and we are excited, that we are now taking it to the next level by offering our technologies together in an integrated way as a single point license for the production of sustainable synthetic fuels,” says Fei Chen, SVP Clean Fuels & Chemicals Technology, Haldor Topsøe.

Marius Brand, Executive Vice President for Sasol 2.0 Transformation added: “Sasol and Haldor Topsøe’s technology relationship spans more than two decades, through which a number of world first technologies were deployed, world-scale units were built and successfully operated. We believe this platform provides a solid foundation to offer solutions to the world and drive towards a sustainable future, specifically for the hard to abate sectors, such as the aviation industry. This technology collaboration is a key element supporting our purpose to innovate for a better world. Our partnership and Sasol’s undisputed leadership in FT technology, positions us well to grow a low carbon products business globally, harnessing renewable resources to produce sustainable fuels and chemicals.”

In addition, new technologies are being developed, such as Topsøe’s electrified reforming platform (e-Reforming and e-Reverse Water Gas Shift), solid oxide electrolysis and Sasol’s next generation FT catalyst to further maximise desired product yields, enhance carbon and hydrogen conversion efficiency, ultimately helping to eliminate fuel and chemical greenhouse gas emissions.

This gives potential customers access to an integrated solution across the entire value chain, from renewable feed sources to liquid fuels. As single-point licensor, Sasol and Topsøe will offer customers all the necessary technology licenses for complete sustainable fuels solutions. This also includes basic engineering, catalyst, hardware and specialised technical support to ensure a bankable and successful project.

Issued by:
Matebello Motloung, Manager: Group Media Relations
Direct telephone: +27 (0) 10 344 9256; Mobile: +27 (0) 82 773 9457
[email protected] 

About Sasol:
Sasol is a global integrated chemicals and energy company. We harness our knowledge and experience to integrate sophisticated technologies and process into our world-scale operating facilities. We safely and sustainably source, produce and market a range of high-value product streams in 30 countries, creating superior value for our customers, shareholders and other stakeholders.

About Sasol’s Information Privacy Policy:
We wish to inform you about the processing of your Personal Information by Sasol South Africa Limited and your rights under applicable data protection law, as interpreted and included in Sasol Information Privacy Policy.

Within our company, only Sasol Group Media Relations will receive your Personal Information to fulfil the purpose of maintaining the relationship with the receiver in his/her capacity as a member of the media. You have the right to request for the correction or deletion of your Personal Information stored by us at address: Sasol Place, 50 Katherine Street, Sandton in Johannesburg. You also have a right to restrict the processing of your Information. To exercise your privacy rights or find out more about Information Privacy Policy, kindly contact our Privacy Office on: [email protected] 

Cision View original content:https://www.prnewswire.com/news-releases/sasol-haldor-topsoe-expand-g2ltm-licensing-collaboration-to-grow-sustainable-synthetic-fuels-and-chemicals-globally-301377582.html

SOURCE Sasol Limited